Short Interest in HLS Therapeutics Inc. (OTCMKTS:HLTRF) Decreases By 96.9%

HLS Therapeutics Inc. (OTCMKTS:HLTRF) saw a significant drop in short interest in March. As of March 31st, there was short interest totalling 100 shares, a drop of 96.9% from the March 15th total of 3,200 shares. Based on an average daily trading volume, of 1,400 shares, the short-interest ratio is currently 0.1 days.

HLS Therapeutics Trading Down 10.0 %

Shares of OTCMKTS:HLTRF traded down $0.33 during trading on Monday, reaching $2.96. The company had a trading volume of 100 shares, compared to its average volume of 941. HLS Therapeutics has a fifty-two week low of $2.22 and a fifty-two week high of $3.56. The stock’s fifty day moving average price is $2.98 and its 200 day moving average price is $2.75.

HLS Therapeutics Company Profile

HLS Therapeutics Inc, a specialty pharmaceutical company, acquires and commercializes pharmaceutical products in the specialty central nervous system and cardiovascular markets in Canada, the United States, and internationally. The company's product portfolio includes Clozaril, an atypical antipsychotic for management of symptoms of treatment-resistant schizophrenia; and Vascepa, an icosapent ethyl capsules for cardiovascular disease.